What happened
- The FDA approved Infilbray (venglustat, Sanofi's Genzyme) tablets on 18 Nov 2026 for the neurological symptoms of type 3 Gaucher disease in people weighing at least 15 kg.
- In a randomized, double-blind study of 43 patients aged 12 and over, people on venglustat did better at week 52 on a combined measure of coordination and thinking than people on enzyme replacement therapy.
- Enzyme replacement treats the body but does not reach the brain; venglustat does.
What we don't know yet
- The FDA lists serious psychiatric risks, including suicidal thoughts and behaviour, and possible eye and pregnancy risks from animal studies.
- 43 patients is a small trial, typical for a rare disease.
Primary sources
- FDA press announcement, 18 Nov 2026Regulator decision
Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.